Literature DB >> 10023311

Stage-specific treatment costs for cervical cancer in the United Kingdom.

J L Wolstenholme1, D K Whynes.   

Abstract

In order to examine the relationship between stage at initial diagnosis and management costs for cervical cancer, a detailed cost audit over 5 years was conducted on a sample of patients diagnosed in 1990 in one U.K. region. The mean costs of managing pre-invasive carcinoma (386 Pounds) were found to be significantly lower than those of stage 1 invasive carcinoma (6623 Pounds) and both were lower than the costs of invasive cancer at stages 2-4 (10,910 Pounds, 10,579 Pounds and 11,035 Pounds, respectively). A comparison of management costs for cervical cancer with those of breast cancer by stage revealed both that the former are invariably higher and that the cost-by-stage profiles for the two diseases are dissimilar.

Entities:  

Mesh:

Year:  1998        PMID: 10023311     DOI: 10.1016/s0959-8049(98)00232-9

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  19 in total

1.  Lifetime effects, costs, and cost effectiveness of testing for human papillomavirus to manage low grade cytological abnormalities: results of the NHS pilot studies.

Authors:  Rosa Legood; Alastair Gray; Jane Wolstenholme; Sue Moss
Journal:  BMJ       Date:  2006-01-06

2.  The planning of cervical cancer screening programmes in eastern Europe: is viral testing a suitable alternative to smear testing?

Authors:  C Sherlaw-Johnson; S Gallivan
Journal:  Health Care Manag Sci       Date:  2000-09

3.  Cost and resource utilization in cervical cancer management: a real-world retrospective cost analysis.

Authors:  I Cromwell; Z Ferreira; L Smith; K van der Hoek; G Ogilvie; A Coldman; S J Peacock
Journal:  Curr Oncol       Date:  2016-02-29       Impact factor: 3.677

4.  An economic model of school-based behavioral interventions to prevent sexually transmitted infections.

Authors:  Keith Cooper; Jonathan Shepherd; Jo Picot; Jeremy Jones; Josephine Kavanagh; Angela Harden; Elaine Barnett-Page; Andrew Clegg; Debbie Hartwell; Geoff Frampton; Alison Price
Journal:  Int J Technol Assess Health Care       Date:  2012-09-21       Impact factor: 2.188

Review 5.  Economic evaluation of human papilloma virus vaccination in the European Union: a critical review.

Authors:  Daniela Koleva; Paola De Compadri; Anna Padula; Livio Garattini
Journal:  Intern Emerg Med       Date:  2011-02-11       Impact factor: 3.397

6.  Financial Burden of Cancer on Patients Treated at a Tertiary Health Facility in South West Nigeria.

Authors:  Muhammad Inuwa Mustapha; Musa Ali-Gombe; Adamu Abdullahi; Adeniyi Adenipekun; Oladapo Babatunde Campbell
Journal:  J West Afr Coll Surg       Date:  2022-06-08

7.  Comparing bivalent and quadrivalent human papillomavirus vaccines: economic evaluation based on transmission model.

Authors:  Mark Jit; Ruth Chapman; Owain Hughes; Yoon Hong Choi
Journal:  BMJ       Date:  2011-09-27

8.  Options for managing low grade cervical abnormalities detected at screening: cost effectiveness study.

Authors: 
Journal:  BMJ       Date:  2009-07-28

9.  Patient side cost and its predictors for cervical cancer in Ethiopia: a cross sectional hospital based study.

Authors:  Alemayehu Hailu; Damen Haile Mariam
Journal:  BMC Cancer       Date:  2013-02-08       Impact factor: 4.430

10.  Vaccinating women previously exposed to human papillomavirus: a cost-effectiveness analysis of the bivalent vaccine.

Authors:  Hugo C Turner; Iacopo Baussano; Geoff P Garnett
Journal:  PLoS One       Date:  2013-09-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.